Literature DB >> 12562834

Apolipoprotein composition and particle size affect HDL degradation by chymase: effect on cellular cholesterol efflux.

Miriam Lee1, Petri T Kovanen, Gabriella Tedeschi, Emanuela Oungre, Guido Franceschini, Laura Calabresi.   

Abstract

Mast cell chymase, a chymotrypsin-like neutral protease, can proteolyze HDL3. Here we studied the ability of rat and human chymase to proteolyze discoidal pre beta-migrating reconstituted HDL particles (rHDLs) containing either apolipoprotein A-I (apoA-I) or apoA-II. Both chymases cleaved apoA-I in rHDL at identical sites, either at the N-terminus (Tyr18 or Phe33) or at the C-terminus (Phe225), so generating three major truncated polypeptides that remained bound to the rHDL. The cleavage sites were independent of the size of the rHDL particles, but small particles were more susceptible to degradation than bigger ones. Chymase-induced truncation of apoA-I yielded functionally compromised rHDL with reduced ability to promote cellular cholesterol efflux. In sharp contrast to apoA-I, apoA-II was resistant to degradation. However, when apoA-II was present in rHDL that also contained apoA-I, it was degraded by chymase. We conclude that chymase reduces the ability of apoA-I in discoidal rHDL particles to induce cholesterol efflux by cleaving off either its amino- or carboxy-terminal portion. This observation supports the concept that limited extracellular proteolysis of apoA-I is one pathophysiologic mechanism leading to the generation and maintenance of foam cells in atherosclerotic lesions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12562834     DOI: 10.1194/jlr.M200420-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  7 in total

Review 1.  Mast cells and metabolic syndrome.

Authors:  Jie Zhang; Guo-Ping Shi
Journal:  Biochim Biophys Acta       Date:  2010-12-23

2.  Pharmaceutical stabilization of mast cells attenuates experimental atherogenesis in low-density lipoprotein receptor-deficient mice.

Authors:  Jing Wang; Sara Sjöberg; Viviane Tia; Blandine Secco; Han Chen; Min Yang; Galina K Sukhova; Guo-Ping Shi
Journal:  Atherosclerosis       Date:  2013-06-07       Impact factor: 5.162

Review 3.  Human umbilical cord blood-derived mast cells: a unique model for the study of neuro-immuno-endocrine interactions.

Authors:  T C Theoharides; D Kempuraj; M Tagen; M Vasiadi; C L Cetrulo
Journal:  Stem Cell Rev       Date:  2006       Impact factor: 5.739

4.  Pegylation of high-density lipoprotein decreases plasma clearance and enhances antiatherogenic activity.

Authors:  Alan R Tall; Nan Wang; Andrew J Murphy; Samuel Funt; Darren Gorman
Journal:  Circ Res       Date:  2013-04-23       Impact factor: 17.367

Review 5.  Mast cell function: a new vision of an old cell.

Authors:  Elaine Zayas Marcelino da Silva; Maria Célia Jamur; Constance Oliver
Journal:  J Histochem Cytochem       Date:  2014-07-25       Impact factor: 2.479

6.  Identification of sites in apolipoprotein A-I susceptible to chymase and carboxypeptidase A digestion.

Authors:  Yoko Usami; Yukihiro Kobayashi; Takahiro Kameda; Akari Miyazaki; Kazuyuki Matsuda; Mitsutoshi Sugano; Kenji Kawasaki; Yuriko Kurihara; Takeshi Kasama; Minoru Tozuka
Journal:  Biosci Rep       Date:  2012-12-06       Impact factor: 3.840

7.  Microenvironmentally controlled secondary structure motifs of apolipoprotein A-I derived peptides.

Authors:  Paola Mendoza-Espinosa; Danai Montalvan-Sorrosa; Victor García-González; Abel Moreno; Rolando Castillo; Jaime Mas-Oliva
Journal:  Mol Cell Biochem       Date:  2014-04-20       Impact factor: 3.396

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.